High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects
| dc.contributor.author | Gao, Pingyi | |
| dc.contributor.examiningcommittee | Kong, Jiming (Human Anatomy and Cell Science) | |
| dc.contributor.examiningcommittee | Kowalec, Kaarina (Pharmacy) | |
| dc.contributor.supervisor | Qi, Dake | |
| dc.date.accessioned | 2024-09-06T18:48:35Z | |
| dc.date.available | 2024-09-06T18:48:35Z | |
| dc.date.issued | 2024-08-19 | |
| dc.date.submitted | 2024-09-06T16:19:13Z | en_US |
| dc.degree.discipline | Pharmacy | |
| dc.degree.level | Master of Science (M.Sc.) | |
| dc.description.abstract | Atypical antipsychotics (AAPs) are primary medications for schizophrenia (SZ). However, their use is frequently associated with the development of adverse metabolic effects, and the mechanisms behind these negative effects remain inadequately elucidated. To investigate the role of macrophage migration inhibitory factor (MIF) in regulating antipsychotic-induced metabolic abnormalities, between 2017 and 2020, a cross-sectional study was conducted, involving 142 healthy individuals and 388 SZ patients undergoing treatment with either typical antipsychotic (TAP) or AAP medications. Symptoms of SZ patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), and measurements of metabolic indices and plasma MIF levels were performed on all individuals. A significant increase in plasma MIF levels was observed in groups receiving five major AAP monotherapies in comparison to healthy controls (all p < 0.0001). There was no such increase shown in the group receiving TAP treatment (p > 0.05). Elevated plasma MIF levels displayed a notable correlation with insulin resistance (β = 0.024, p = 0.020), as well as with the levels of triglycerides (β = 0.019, p = 0.001) and total cholesterol (β = 0.012, p = 0.038) in the groups receiving AAPs. However, while the TAP group also displayed certain metabolic dysfunction compared to healthy controls, no significant association was evident with plasma MIF levels (all p > 0.05). In conclusion, plasma MIF levels exhibit a distinctive correlation with metabolic abnormalities triggered by AAPs. Hence, there is potential for further development of MIF as a distinctive marker for monitoring adverse metabolic effects induced by AAPs in clinical settings. | |
| dc.description.note | October 2024 | |
| dc.description.sponsorship | N/A | |
| dc.identifier.uri | http://hdl.handle.net/1993/38537 | |
| dc.language.iso | eng | |
| dc.subject | Atypical Antipsychotics | |
| dc.subject | Insulin Resistance | |
| dc.subject | Metabolic Adverse Effects | |
| dc.title | High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects | |
| local.subject.manitoba | no | |
| oaire.awardNumber | N/A | |
| oaire.awardTitle | N/A | |
| oaire.awardURI | N/A | |
| project.funder.identifier | N/A | |
| project.funder.name | N/A |